Skip to main content
. Author manuscript; available in PMC: 2008 Dec 1.
Published in final edited form as: J Mol Cell Cardiol. 2007 Sep 12;43(6):664–666. doi: 10.1016/j.yjmcc.2007.09.002

Figure 1.

Figure 1

Schematic demonstrating the relationship between angiotensin II, matrix metalloproteinase-9 (MMP-9), and angiotensin converting enzyme (ACE) inhibitors in preventing adverse LV remodeling.